- Home
- MDGL vs IVZ Comparison
MDGL vs IVZ Comparison
Compare MDGL & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- IVZ
- Stock Information
- Founded
- MDGL 2011
- IVZ 1935
- Country
- MDGL United States
- IVZ United States
- Employees
- MDGL N/A
- IVZ N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- IVZ Investment Managers
- Sector
- MDGL Health Care
- IVZ Finance
- Exchange
- MDGL Nasdaq
- IVZ Nasdaq
- Market Cap
- MDGL 7.5B
- IVZ 7.4B
- IPO Year
- MDGL N/A
- IVZ 1995
- Fundamental
- Price
- MDGL $323.98
- IVZ $15.20
- Analyst Decision
- MDGL Buy
- IVZ Hold
- Analyst Count
- MDGL 10
- IVZ 14
- Target Price
- MDGL $354.75
- IVZ $19.77
- AVG Volume (30 Days)
- MDGL 317.3K
- IVZ 5.6M
- Earning Date
- MDGL 05-06-2025
- IVZ 04-22-2025
- Dividend Yield
- MDGL N/A
- IVZ 5.40%
- EPS Growth
- MDGL N/A
- IVZ N/A
- EPS
- MDGL N/A
- IVZ 1.18
- Revenue
- MDGL $180,133,000.00
- IVZ $6,067,000,000.00
- Revenue This Year
- MDGL $228.41
- IVZ N/A
- Revenue Next Year
- MDGL $73.44
- IVZ $4.89
- P/E Ratio
- MDGL N/A
- IVZ $12.90
- Revenue Growth
- MDGL N/A
- IVZ 6.13
- 52 Week Low
- MDGL $189.00
- IVZ $14.16
- 52 Week High
- MDGL $377.46
- IVZ $19.55
- Technical
- Relative Strength Index (RSI)
- MDGL 45.41
- IVZ 37.94
- Support Level
- MDGL $310.00
- IVZ $14.80
- Resistance Level
- MDGL $350.50
- IVZ $16.22
- Average True Range (ATR)
- MDGL 13.02
- IVZ 0.38
- MACD
- MDGL -1.72
- IVZ 0.06
- Stochastic Oscillator
- MDGL 34.52
- IVZ 29.31
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of October 2024, the firm had $1.792 trillion in assets under management spread among its equity (58% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (10%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's us retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 29% of its AUM sourced from Europe, Africa, and the Middle East (14%) and Asia (15%).